Effect of immuno-oncology on clinical and economic outcomes for a selection of cancers in Italy
IO drugs introduction in Italy between 2008 and 2019 was associated with a significant decrease in deaths from each cancer and, consequently, in savings in indirect costs related to premature mortality.
Authors
- Filippo de Braud (ORCID: https://orcid.org/0000-0003-0103-730X)
- Federica Perrone (ORCID: https://orcid.org/0000-0003-4406-8245)
- Paolo A. Ascierto (ORCID: https://orcid.org/0000-0002-8322-475X)
- Beatrice Canali (ORCID: https://orcid.org/0000-0003-0556-0886)
- Francesco Grossi (ORCID: https://orcid.org/0000-0001-8412-3136)
- F Fiorentino (ORCID: https://orcid.org/0000-0003-2092-3593)
- Cristina Mezzanotte (ORCID: https://orcid.org/0000-0002-8854-5149)
- Giovanni Patanè
- Giovanni Apolone (ORCID: https://orcid.org/0000-0001-5179-104X)
- Massimo Riccaboni
- Guido Didoni
- Giuseppina Zapparelli
- Laura Candelora (ORCID: https://orcid.org/0009-0005-7431-5325)
- Angelo Costanzo (ORCID: https://orcid.org/0009-0007-5528-138X)
Institutions
- University of Insubria (IT)
- Bristol-Myers Squibb (Germany) (DE)
- Istituto Universitario di Studi Superiori di Pavia (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Bristol-Myers Squibb (Italy) (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1080/14737167.2025.2493130
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00